AGEN Delivers Over 150% In Less Than 4 Months

Source and reference

source on Google Add Now Shares of Agenus Inc. ( AGEN ) climbed to a 52-week intraday high of $8.70 yesterday, following the company's announcement of an oversubscribed private placement of up to $340 million to support its planned registrational Phase 3 ROBBIN trial evaluating neoadjuvant botensilimab plus balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer. The financing includes $85 million in upfront gross proceeds, before deducting offering expenses, with the potential to raise up to an additional $255 million upon the full exercise of the accompanying purchase warrants. Subscribe to continue reading the article. This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription. Start Free Trial FREE 7-Day Trial - No Payment Required Already subscribed? Sign in For comments and feedback...